search
Back to results

Safety and Efficacy of Injectable Poly-L-Lactic Acid for Volume Loss in the Temples Using Dual Plane Injections

Primary Purpose

Lipoatrophy, Aging

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Sculptra aesthetic
Sponsored by
Sadick Research Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lipoatrophy

Eligibility Criteria

25 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPAA authorization Healthy males or females over 25 years old with temporal hollows volume deficit of Grade 2 to 4 on the Galderma Temple Volume Deficit Scale Subjects with Fitzpatrick photo skin types I-IV Subjects who agree not to have any procedures affecting facial wrinkles (e.g. filler, botulinum toxin, radiofrequency, laser, intense-pulsed light, ultrasound) for the duration of the study Subjects who do agree not to have any other procedures affecting skin quality (microdermabrasion, peels, acne treatments, etc.) for the duration of the study Subjects who understand this study and are able to follow study instructions and are willing to attend the required study visits Subjects who agree to be photographed for research reasons and their identity may not be concealed in these photographs. Exclusion Criteria: Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy Subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, intrauterine device, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy or bilateral oophorectomy. Subjects who cannot understand or are not willing to comply with the requirements of the study Subjects who have a known allergy to poly-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol or any anesthetic Subjects who have taken any NSAIDs (aspirin, ibuprofen, etc.) within 7 days before treatment Subjects who have taken acetaminophen 24 hours before treatment Subjects who have had fillers or botulinum toxin in the treatment area in the past 12 months Subjects who have had treatments with poly-L-lactic acid in the face at any time Subjects who have had any kind of facial dermabrasion, chemical peel, laser, or IPL treatment including superficial treatments for aesthetic reasons in the past 6 months or for the duration of the study Subjects who does not agree to avoid using tanning beds or intensive exposure to the sun 2 two weeks prior to each office visit. Subjects who have any dermatologic conditions including acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, infection or scars within the treatment area Subjects who have an active inflammatory process (skin eruptions such as cysts, pimples, rashes or hives) or infection within the treatment area Subjects who have any known cancer including skin cancers (basal cell carcinoma, squamous cell carcinoma and melanoma) Subjects who have had systemic corticosteroid therapy in the past 6 months or for the duration of the study Subjects with a known history of poor wound healing Subjects with a known history of keloids (excessive scarring) Subjects who are HIV positive Subjects who have an existing medical condition that the Investigator considers may put the subject at risk or compromise their participation in the study Subjects who have participated in another research study in the past 30 days Subjects who are currently involved in any injury litigation claims

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Sculptra® Aesthetic

    Arm Description

    Outcomes

    Primary Outcome Measures

    Clinical evaluation of PLLA injection for efficacy, to restore the volume loss in temporal area
    at least one degree of improvement in the temporal area volume using the Galderma Temple Volume Deficit Scale (Moradi et al Dermatol Surg. 2020 Sep;46(9): 1148-1154) and GAIS at the last follow up as compared to baseline.

    Secondary Outcome Measures

    Improvement of facial skin laxity
    Improvement of facial skin laxity will be defined as at least 1 point of improvement in the facial area using the 10-point facial laxity rating scale (Silva Hector, Dermatol Surg.2016 Dec;42(12):1370-1379) from baseline throughout week 36.
    Adverse events
    Safety will be assessed throughout the study by monitoring adverse events clinically and by Ultrasound imaging.

    Full Information

    First Posted
    November 2, 2022
    Last Updated
    November 7, 2022
    Sponsor
    Sadick Research Group
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05608239
    Brief Title
    Safety and Efficacy of Injectable Poly-L-Lactic Acid for Volume Loss in the Temples Using Dual Plane Injections
    Official Title
    Prospective, Single-site, Open Label Study to Assess the Safety and Efficacy of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Volume Loss in the Temples Using Dual Plane Injections
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    November 2022 (Anticipated)
    Primary Completion Date
    July 2023 (Anticipated)
    Study Completion Date
    November 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Sadick Research Group

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Temporal volume loss is part of the natural aging process of the face. It is primarily the consequence of fat pad atrophy, but bone loss, ligament weakening, soft tissue, and muscle also contribute. . The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples.
    Detailed Description
    This is a prospective, single-site, open label study to assess the safety and efficacy of injectable Poly-L-Lactic Acid (Sculptra aesthetic) for volume loss in the temples using dual plane injections. Eligible subjects will get up to 3 treatments four weeks apart with poly-L-lactic acid, (Sculptra) in the temples. After the treatments, subjects will return to the research site 1 month and 6 months post last treatment for follow up visits.Eligible subjects will get up to 3 treatment sessions 4 weeks apart with ether Sculptra® Aesthetic or saline following a randomized list. During the study period, subjects will return to the research site for visits at 5 and 6 months post baseline (±7 days).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lipoatrophy, Aging

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Sculptra® Aesthetic
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    Sculptra aesthetic
    Intervention Description
    The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
    Primary Outcome Measure Information:
    Title
    Clinical evaluation of PLLA injection for efficacy, to restore the volume loss in temporal area
    Description
    at least one degree of improvement in the temporal area volume using the Galderma Temple Volume Deficit Scale (Moradi et al Dermatol Surg. 2020 Sep;46(9): 1148-1154) and GAIS at the last follow up as compared to baseline.
    Time Frame
    16 weeks
    Secondary Outcome Measure Information:
    Title
    Improvement of facial skin laxity
    Description
    Improvement of facial skin laxity will be defined as at least 1 point of improvement in the facial area using the 10-point facial laxity rating scale (Silva Hector, Dermatol Surg.2016 Dec;42(12):1370-1379) from baseline throughout week 36.
    Time Frame
    16 weeks
    Title
    Adverse events
    Description
    Safety will be assessed throughout the study by monitoring adverse events clinically and by Ultrasound imaging.
    Time Frame
    16 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    25 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPAA authorization Healthy males or females over 25 years old with temporal hollows volume deficit of Grade 2 to 4 on the Galderma Temple Volume Deficit Scale Subjects with Fitzpatrick photo skin types I-IV Subjects who agree not to have any procedures affecting facial wrinkles (e.g. filler, botulinum toxin, radiofrequency, laser, intense-pulsed light, ultrasound) for the duration of the study Subjects who do agree not to have any other procedures affecting skin quality (microdermabrasion, peels, acne treatments, etc.) for the duration of the study Subjects who understand this study and are able to follow study instructions and are willing to attend the required study visits Subjects who agree to be photographed for research reasons and their identity may not be concealed in these photographs. Exclusion Criteria: Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy Subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, intrauterine device, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy or bilateral oophorectomy. Subjects who cannot understand or are not willing to comply with the requirements of the study Subjects who have a known allergy to poly-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol or any anesthetic Subjects who have taken any NSAIDs (aspirin, ibuprofen, etc.) within 7 days before treatment Subjects who have taken acetaminophen 24 hours before treatment Subjects who have had fillers or botulinum toxin in the treatment area in the past 12 months Subjects who have had treatments with poly-L-lactic acid in the face at any time Subjects who have had any kind of facial dermabrasion, chemical peel, laser, or IPL treatment including superficial treatments for aesthetic reasons in the past 6 months or for the duration of the study Subjects who does not agree to avoid using tanning beds or intensive exposure to the sun 2 two weeks prior to each office visit. Subjects who have any dermatologic conditions including acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, infection or scars within the treatment area Subjects who have an active inflammatory process (skin eruptions such as cysts, pimples, rashes or hives) or infection within the treatment area Subjects who have any known cancer including skin cancers (basal cell carcinoma, squamous cell carcinoma and melanoma) Subjects who have had systemic corticosteroid therapy in the past 6 months or for the duration of the study Subjects with a known history of poor wound healing Subjects with a known history of keloids (excessive scarring) Subjects who are HIV positive Subjects who have an existing medical condition that the Investigator considers may put the subject at risk or compromise their participation in the study Subjects who have participated in another research study in the past 30 days Subjects who are currently involved in any injury litigation claims
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Neil Sadick, MD
    Phone
    2127727242
    Email
    nssderm@sadickdermatology.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Namrata Oza
    Phone
    2127727242
    Email
    noza@sadickdermatology.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Safety and Efficacy of Injectable Poly-L-Lactic Acid for Volume Loss in the Temples Using Dual Plane Injections

    We'll reach out to this number within 24 hrs